Evidence map›Paper›PMID 30953519›Full record

ArticleJournal of translational medicine2019

Interleukin 32 expression in human melanoma.

Helicia Paz, Jennifer Tsoi, Anusha Kalbasi, Catherine S Grasso, William H McBride, Dörthe Schaue, Lisa H Butterfield, Deena M Maurer, Antoni Ribas, Thomas G Graeber and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Interleukin 32 Promotes Foxp3Frontiers in cell and developmental biology · 2021
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Helicia PazDepartment of Surgery, University of California, Los Angeles, 10833 Le Conte Ave, Los Angeles, CA, 90095, USA.ORCID 0000-0001-9316-1185
Jennifer TsoiDepartment of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, CA, 90095, USA.
Anusha KalbasiDepartment of Surgery, University of California, Los Angeles, 10833 Le Conte Ave, Los Angeles, CA, 90095, USA.
Catherine S GrassoDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
William H McBrideDepartment of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Dörthe SchaueDepartment of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Lisa H ButterfieldDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
Deena M MaurerDepartment of Immunology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
Antoni RibasDepartment of Surgery, University of California, Los Angeles, 10833 Le Conte Ave, Los Angeles, CA, 90095, USA.
Thomas G GraeberDepartment of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, CA, 90095, USA.
James S EconomouDepartment of Surgery, University of California, Los Angeles, 10833 Le Conte Ave, Los Angeles, CA, 90095, USA. jeconomou@mednet.ucla.edu.
University of California, Los Angeles · USUniversity of Pittsburgh · US

Funding

Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9M
Radiotherapy-induced tumor immunityR01CA191234 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SCHAUE, DORTHE · 2015 to 2019
$1.8M
Training Program in Skin Biology and CancerT32CA175294 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2014 to 2018
$973k
NCI NIH HHS P50 CA121973NCI NIH HHS R01 CA191234NCI NIH HHS T32 CA175294
6 · The paper itself

Abstract

backgroundVarious proinflammatory cytokines can be detected within the melanoma tumor microenvironment. Interleukin 32 (IL32) is produced by T cells, NK cells and monocytes/macrophages, but also by a subset of melanoma cells. We sought to better understand the biology of IL32 in human melanoma.

methodsWe analyzed RNA sequencing data from 53 in-house established human melanoma cell lines and 479 melanoma tumors from The Cancer Genome Atlas dataset. We evaluated global gene expression patterns associated with IL32 expression. We also evaluated the impact of proinflammatory molecules TNFα and IFNγ on IL32 expression and dedifferentiation in melanoma cell lines in vitro. In order to study the transcriptional regulation of IL32 in these cell lines, we cloned up to 10.5 kb of the 5' upstream region of the human IL32 gene into a luciferase reporter vector.

resultsA significant proportion of established human melanoma cell lines express IL32, with its expression being highly correlated with a dedifferentiation genetic signature (high AXL/low MITF). Non IL32-expressing differentiated melanoma cell lines exposed to TNFα or IFNγ can be induced to express the three predominant isoforms (α, β, γ) of IL32. Cis-acting elements within this 5' upstream region of the human IL32 gene appear to govern both induced and constitutive gene expression. In the tumor microenvironment, IL32 expression is highly correlated with genes related to T cell infiltration, and also positively correlates with high AXL/low MITF dedifferentiated gene signature.

conclusionsExpression of IL32 in human melanoma can be induced by TNFα or IFNγ and correlates with a treatment-resistant dedifferentiated genetic signature. Constitutive and induced expression are regulated, in part, by cis-acting sequences within the 5' upstream region.

Indexed as

BiopsyCell DedifferentiationCell Line, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansInterferon-gammaInterleukinsLymphocytes, Tumor-InfiltratingMelanomaMicroarray AnalysisNeoplasm MetastasisSkin NeoplasmsTranscriptomeTumor MicroenvironmentTumor Necrosis Factor-alphaIL32 protein, humanInterferon-gammaInterleukinsTumor Necrosis Factor-alphaIL32 transcriptional regulationImmune infiltrationInterleukin 32 (IL32)Melanoma dedifferentiationMyeloid polarization

Identifiers

PMID30953519
PMCPMC6449995
OpenAlexW2946921022

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.